Targeting miR-155 to Treat Experimental Scleroderma

por Yan, Qingran, Chen, Jie, Li, Wei, Bao, Chunde, Fu, Qiong
Publicado 2016

Corrigendum: Targeting miR-155 to Treat Experimental Scleroderma

por Yan, Qingran, Chen, Jie, Li, Wei, Bao, Chunde, Fu, Qiong
Publicado 2016

Gangrene of nose in granulomatosis with polyangiitis

por Fan, Wei, Zhang, Chunyan, Yin, Hanlin, Zhang, Wei, Yan, Qingran
Publicado 2022

Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer

por Yan, Qingran, Liu, Bei, Wang, Jieying, Yin, Hanlin, Li, Qianqian, Lu, Liangjing
Publicado 2023

High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center

por Huang, Linlin, Fu, Qiong, Ye, Yan, Lin, Yanwei, Yan, Qingran, Chen, Sheng
Publicado 2021

Prevention of Immune Nephritis by the Small Molecular Weight Immunomodulator Iguratimod in MRL/lpr Mice

por Yan, Qingran, Du, Fang, Huang, Xinfang, Fu, Qiong, Chen, Sheng, Dai, Dai, Bao, Chunde
Publicado 2014

Duration biased distribution of clinical and immunological phenotypes in active SLE

por Yan, Qingran, Liu, Bei, Yang, Minjie, Li, Qianqian, Wang, Jieying, Li, Ting, Lu, Liangjing
Publicado 2022

Association of Cytomegalovirus Infection With Anti-MDA5 Antibody-Positive Dermatomyositis: A Prospective Cohort Study

por Huang, Linlin, Zhu, Wenbo, Ye, Yan, Wu, Xiaoping, Yan, Qingran, Wang, Zhiqing, Lin, Yanwei, Chen, Sheng
Publicado 2021

Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study

por Yan, Qingran, Zhang, Mei, Du, Fang, Kang, Yuening, Ye, Ping, Li, Qianqian, Liu, Bei, Dai, Min, Bao, Chunde
Publicado 2023

Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome

por Li, Qianqian, Li, Rui, Yin, Hanlin, Wang, Suli, Liu, Bei, Li, Jun, Zhou, Mi, Yan, Qingran, Lu, Liangjing
Publicado 2022

Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis

por Ye, Yan, Liu, Mei, Tang, Longhai, Du, Fang, Liu, Yuanhua, Hao, Pei, Fu, Qiong, Guo, Qiang, Yan, Qingran, Zhang, Xiaoming, Bao, Chunde
Publicado 2019

Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study

por Kang, Yuening, Yan, Qingran, Fu, Qiong, Wang, Ran, Dai, Min, Du, Fang, Dai, Qing, Ye, Ping, Wu, Chunmei, Lu, Liangjing, Bao, Chunde
Publicado 2020

Quantitative infrapatellar fat pad signal intensity alteration as an imaging biomarker of knee osteoarthritis progression

por Cen, Han, Yan, Qingran, Meng, Tao, Chen, Zhongshan, Zhu, Jimin, Wang, Yuanyuan, Ruan, Guangfeng, Wang, Tian, Han, Weiyu, Hunter, David, Ding, Changhai
Publicado 2023

Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression

por Shen, Lichong, Yin, Hanlin, Sun, Li, Zhang, Zhiliang, Jin, Yuyang, Cao, Shan, Fu, Qiong, Fan, Chaofan, Bao, Chunde, Lu, Liangjing, Zhan, Yifan, Xu, Xiaojiang, Chen, Xiaoxiang, Yan, Qingran
Publicado 2023

Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, contr...

por Yan, Qingran, Du, Fang, Kang, Yuening, Ye, Ping, Wang, Xiaodong, Xu, Jianhua, Tang, Jianping, Wang, Niansong, Jiang, Gengru, Li, Zhijun, Wang, Xuan, Xue, Qin, Huang, Xinfang, Zhang, Xiaoyan, Zhou, Ying, Dai, Min, Bao, Chunde
Publicado 2021